

# Index

*Note:* Page numbers followed by *f* and *t* denote figures and tables, respectively

## A

- Access to care, disparities in, 58
- Adaptive immunity, modulation of, 297–300, 298*f*
- Advisory Committee on Immunization Practices (ACIP), 15
- Age, and oral/cervical HPV infection, 216
- Alcohol consumption
  - disparities in, 61–62
  - and squamous cell carcinoma, 33, 37–38, 44
  - head and neck squamous cell carcinoma, 33, 37–38, 44
  - of oropharynx, 25
- Alternative lengthening of telomeres (ALT), 72
- Alveolar bone loss (ABL), and head and neck squamous cell carcinoma, 39
- Amplification, 111, 112
- Anaphase-promoting complex/cyclosome (APC/C), 88
- Anatomy, 240
  - of oropharynx, 196, 197*f*
- Anderson, Teresa A., 25
- Androphy, Elliot J., 103
- Antigen processing machinery (APM), 297, 298*f*
- Antigen-presenting cells (APCs), 294, 296
- APOBEC enzymes, 185–186

## B

- Behavioral correlates
  - of HPV-associated OPSCC, 24–32
  - alcohol consumption, 25
  - prevalence of, 32
  - risk factors of, 27–30*r*, 31*f*
  - sex, 25, 31*f*

- of non-HPV-associated OPSCC, 32–33
- Bevacizumab, for OPSCC/CSCC, 221
- Biologic determinants, of OPSCC disparities, 63–64
- Brd4, role in viral replication, 121–122

## C

- Caenorhabditis elegans* (*C. elegans*), 133, 134
- Cancer. *See Individual entries*
  - prevention, 14–17
  - prophylaxis, 14, 17
- Carcinoma in situ (CIS), 9
- CASP8 mutations, in HPV-positive HNSCC, 183–184
- Cervarix®, for HPV infection, 14, 302, 303
- Cervical intraepithelial neoplasia grade 3 (CIN3), 9
- Cervical lymph nodes, 196, 197*f*
- Cervical squamous cell carcinoma (CSCC)
  - HPV-positive
    - FGFR3 mutations in, 181
    - recurrent genomic alterations, comparison of, 184–186
  - and OPSCC, similarities between, 214–224
  - epidemiology, 217
  - etiology of, 217–218
  - HPV on outcome, impact of, 221–222
  - HPV-type distribution, 218
  - molecular pathogenesis, 223–224
  - primary and secondary prevention, 222–223
  - prognosis, 219–220
  - risk factors, 218–219
  - treatment, 220–221

Cetuximab  
 for HNSCC, 271  
 for OPSCC/CSCC, 221  
 Chemoradiation, 220–221, 235  
 Chemotherapy, induction, 270–271  
*Chlamydia trachomatis*, 16, 219  
 Cisplatin  
 -based chemoradiation, for cervical  
 cancer, 220–221  
 for Fanconi anemia, 7  
 for HNSCC, 271  
 Clinical evaluation, of oropharyngeal cancer,  
 201, 202f  
 Clinical presentation, of oropharyngeal cancer,  
 195–200  
 posterior pharyngeal wall cancer, 200  
 soft palate cancers, 200  
 tongue base cancer, 200  
 tonsil cancer, 199–200, 199f  
 Couch, Marion, 195  
 CTLA-4, 275  
*CTNNA3*, 5  
 Culleton, Sara P., 103  
 Cytotoxic T lymphocytes (CTLs), 294,  
 296, 299

## D

Da Vinci surgical system, 232f  
 De Costa, Anna-Maria, 243  
 Dendritic cells (DCs), 294, 296  
 Dental health, and head and neck squamous  
 cell carcinoma, 39  
 2'-Deoxyguanosine 5'-monophosphate  
 (dGMP), 6  
 Detection and treatment disparities, 60–61  
 Diphtheria toxoid and acellular pertussis  
 vaccine (Tdap), 15  
*DLG2*, 5  
*DMD*, 5  
 DNA  
 double strand breaks (DSBs), 6, 72, 83  
 repair, 274  
 driving mutagenesis by corrupting,  
 83–85  
 pathways, 109–111  
 sequence requirements, 114–115, 115r  
 DNA damage response (DDR), 274  
 eukaryotic replication, 109–111, 110r, 112  
 viral replication, 122–123  
 DNA-protein complex, 116  
 Docetaxel, cisplatin, and 5-FU (TPF),  
 for HNSCC, 271  
 Doçi, Colleen L., 153

## E

E1 protein, 115–117  
 phosphorylation of, 118–119  
 E1:E2 interaction, 118  
 E2 protein, 75–76, 115–116, 117–118  
 molecular targets of, 82r  
 phosphorylation of, 118–119  
 E5 protein, 73–74, 120  
 molecular targets of, 81r  
 E6 protein, 6, 45, 70–71, 119–120  
 disrupting p53/Rb tumor suppression  
 network, 156–157  
 interaction of TP53 with, 178  
 molecular targets of, 78r  
 E7 protein, 6, 45, 71–73, 119–120  
 disrupting p53/Rb tumor suppression  
 network, 156–157  
 interaction of TP53 with, 178  
 molecular targets of, 79–80r  
 Economopoulou, Panagiota, 213  
 Epidemiology, of HPV-associated OPSCC,  
 1–18  
 Epidermal growth factor receptor (EGFR),  
 73–74, 77  
 inhibition, 269–270  
 Epithelial-mesenchymal transition (EMT),  
 77–78, 80  
 Epstein-Barr virus (EBV) infection, and  
 nasopharyngeal carcinoma, 186, 187  
 Ermel, Aaron C., 25  
 Esophageal squamous cell carcinoma (ESCC),  
 K-RAS mutations in, 181–182  
 Eukaryotic replication, 107–111  
 DNA damage response and repair  
 pathways, 109–111, 110r  
 general components and process, 107–109,  
 108f  
 Extracellular-signal-regulated kinases 2  
 (ERK2). *See* Mitogen-activated protein  
 kinase 1 (MAPK1) mutations

## F

Fanconi anemia (FA), 7, 11  
 Ferris, Robert L., 291  
 FGFR3 mutations, in HPV-positive HNSCC, 181  
*FHIT*, 5, 6  
 Field cancerization, 208  
 Fluorescence in situ hybridization (FISH), 4  
 Food and Drug Administration (FDA), 14  
 Fork stalling and template switching  
 (FoSTeS), 5  
*FOXE1*, 4  
*FRA3B*, 6

**G**

- Gardasil®, for HPV infection, 14, 302, 303
- Gender, and oral/cervical HPV infection, 216
- Gene mutations in HPV-positive and HPV-negative HNSCC, comparison of, 174–177, 174f, 175t, 176f
- Genomic instability, 114
- Gildener-Leapman, Neil, 231
- Glover, Sandra H., 43
- Gollin, Susanne M., 1
- Grandis, Jennifer R., 171

**H**

- Head and Neck Cancer Inventory (HNCI), 238
- Head and neck squamous cell carcinoma (HNSCC), 1, 3, 24, 43–44
  - behavioral correlates of, 32–39
    - alcohol consumption, 33, 37–38
    - dental health, 39
    - marijuana use, 38
    - nutrition, 39
    - sex, 33–37, 34–36r
    - tobacco use, 37–38
  - development, HPV expression, 47–48
  - disparities in
    - HPV prevalence/activity, 55, 56
    - incidence and mortality rates, 48–49
  - gene mutations in HPV-positive and HPV-negative HNSCC, comparison of, 174–177, 174f, 175t, 176f
  - HPV-associated
    - biology of, 45–46
    - incidence of, 153–155, 155f
    - microRNAs in, 143–144r
    - PI3 K-mTOR signaling circuitry in, targeting, 160–161
    - prevalence of, 153–155, 155f
  - HPV biomarkers of, 46–47
  - HPV-positive, mutational profile of, 170–188
- Health insurance disparities, 58–60
- High throughput viral integration detection (HIVID), 5
- Histone deacetylases (HDAC), 71, 72
- Histopathology, of HPV (+) oropharyngeal cancer, 205, 206f
- HIV-infected individuals, 40, 162, 219, 292
  - behavioral correlates of oral HPV infection in, 26, 31
- HPV infection
  - biology of, 2–7
  - early infection, 106–107, 106f

- oral versus cervical
  - age and gender, 216
  - contrary to genital HPV infection, 214–215
  - HPV-type distribution, 216–217
  - natural history, 215
  - transmission, 215–216
  - prevalence of, 9–11
  - prevention of, 14–17
  - transmission of, 7–8
- HPV oncogene-induced malignant transformation, 76–89
  - cellular growth and immortalization, 76–80
  - chromosomal instability and mitosis, 86–89
  - driving mutagenesis by corrupting DNA repair, 83–85
  - immune system evasion, 80–82
- HPV (+) oropharyngeal cancer
  - histopathology and immunohistochemistry in, 205, 206f
  - patterns of recurrence, 208–209
  - PI3 K-mTOR signaling circuitry in, 161–162
  - second primary tumors in, 208–209
  - staging dilemma for, 209
  - treatment de-intensification for, 267–268r
- HPV virology, 69–91
  - E2 transcription factor, 75–76
  - E5 oncogene, 73–74
  - E6 oncogene, 70–71
  - E7 oncogene, 71–73
  - future considerations of, 89–91
- Human papillomavirus (HPV), 44–45.
  - See also Individual entries*
  - biomarkers of, 46–47
  - expression, and HNSCC development, 47–48
  - infection. *See* HPV infection
  - investigational immunotherapies, 303–404
  - life cycle of, 213–214, 292–294, 293f
  - preventive vaccines, 302–303
  - signature, 46
  - as treatment response indicator, 244–253, 246–252r
  - types of, 2
- Hypoxia, radiation sensitivity on, 258–259

**I**

- IFN-stimulated response element (ISRE), 294
- Image-guided radiation (IGRT), 263
- Imaging assessment of oropharyngeal cancer, 202–204, 203f, 204f

Immune checkpoints in HPV-related immune evasion, role of, 300–301, 300f

Immune modulation, in HPV-related carcinogenesis, 291–304  
 general evidence for, 292  
 immune checkpoints in HPV-related immune evasion, role of, 300–301, 300f  
 immune evasion in HPV persistence and malignant transformation, role of adaptive immunity, modulation of, 297–300, 298f  
 HPV life cycle, as strategy, 292–294, 293f  
 innate immunity, modulation of, 294–297, 295f  
 in response to HPV-related malignancy treatment, 301–302

Immune responses, radiation sensitivity on, 259–262

Immune system  
 evasion, 80–82  
 miR-9 expression in, 139–141, 140r

Immunohistochemistry, of HPV (+)  
 oropharyngeal cancer 205, 206f

Immunosuppression, 219

Immunotherapies, for HPV infection, 303–304

In situ hybridization (ISH), 46

Induction chemotherapy, 270–271

Innate immunity, modulation of, 294–297, 295f

Intensity-modulated radiation therapy (IMRT), 263

Interferon alpha (IFN- $\alpha$ ), 294, 295

Interferon beta (IFN- $\beta$ ), 294, 295

Interferon gamma (IFN- $\gamma$ ), 294–296

Interferon regulatory factors (IRF), 294

Interferon signaling, 294–295, 295f

Interleukin-1 (IL-1), 296

Interleukin-2 (IL-2), 296, 299

Interleukin-4 (IL-4), 296

Interleukin-5 (IL-5), 296

Interleukin-6 (IL-6), 296

Interleukin-8 (IL-8), 295

Interleukin-10 (IL-10), 296

Interleukin-13 (IL-13), 296

Interleukin-18 (IL-18), 295

Invasive cervical cancer (ICC), 9

ISG factor-3 (ISGF-3), 294

**J**

JAK-STAT signaling, IFN-induced, 294, 295

**K**

Kanginakudru, Sriramana, 103

Kimble, Randall J., 243

Kim, Seungwon, 231, 291

K-RAS mutations  
 in HPV-positive CSCC, 185  
 in HPV-positive HNSCC, 181–182, 185

**L**

Life cycle of HPV, 213–214, 292–294, 293f

Lifestyle determinants, of OPSCC disparities, 62

Li, Hua, 171

*Listeria monocytogenes*, 304

Low molecular mass protein 2 (LMP-2), 297

**M**

Marijuana use, and head and neck squamous cell carcinoma, 38

Matrka, Marie C., 69

Men who have sex with men (MSM). *See* HIV-infected individuals and squamous cell carcinoma of the oropharynx, 31

Meningococcal conjugate vaccine (MenACWY), 15

MH-mediated break-induced replication (MMBIR), 5

MicroRNA  
 as biomarkers, 141–142, 143–144r  
 profiles, of HPV-associated OPSCC, 133–147, 137r, 138f  
 historical perspectives of, 133–134  
 immune system, miR-9 expression in, 139–141, 140r  
 salivary diagnosis, 146–147  
 as therapeutic targets, 145–146

MicroRNA-9 (miR-9) expression, in immune system, 139–141, 140r

Miller, Daniel Lee, 133

Mitogen-activated protein kinase 1 (MAPK1) mutations  
 in HPV-positive CSCC, 185  
 in HPV-positive HNSCC, 182, 185

Mitomycin C, for Fanconi anemia, 7

Mitosis, chromosomal instability and, 86–89

Molecular pathogenesis, of OPSCC/CSCC, 223–224

Monocyte chemoattractant protein 1 (MCP-1), 295

Moore, Michael, 195

Multiple sclerosis (MS), 17

- Mutational profile, of HPV-positive HNSCC, 170–188  
 gene mutations in HPV-positive and HPV-negative HNSCC, comparison of, 174–177, 174*f*, 175*t*, 176*f*  
 mutation frequency, implications of, 179–184  
 recurrent genomic alterations, comparison of, 184–186  
 TP53 mutations, 176–178
- N**
- Nasopharyngeal carcinoma (NPC)  
 FGFR3 mutations in, 181  
 gene alterations in, 186–187
- Natural history of oral/cervical HPV infection, 215
- Natural killer (NK) cells, 294, 296  
*NBEA*, 5
- Neck mass, presentation and evaluation of, 198–199, 198*f*
- Nimorazole, for hypoxia, 259
- NOTCH1 mutations, in HPV-positive HNSCC, 182–183
- Nuclear factor  $\kappa$ B (NF- $\kappa$ B), 296
- Nutrition, and head and neck squamous cell carcinoma, 39
- O**
- ObamaCare. *See* Patient Protection and Affordable Care Act of 2010
- Onion-skin replication (OSR), 114
- Oral and pharyngeal cancers (O&PC)  
 disparities in HPV prevalence/activity, 54–58  
 disparities in incidence and mortality rates for, 48–54  
 age-adjusted, 48, 49*t*  
 decreasing over time, 52–53, 53*f*  
 national and regional data, 49–51
- Oral HPV prevalence, determinants of, 62–63
- Oral sex, 216, 243. *See also* Sex as risk factor, 12, 26, 27–30*t*  
 in whites, 63
- Oropharyngeal hemorrhage, 232, 234–236, 239, 240
- P**
- p53-mediated apoptotic cell death, 255–257
- p53/Rb tumor suppression network, E6 and E7 viral proteins disrupting, 156–157
- Paclitaxel, for HNSCC, 271
- Papillomavirus episteme (PaVE), 103
- Papillomaviruses (PVs), 103–123. *See also* Human papillomavirus (HPV)  
 classification of, 103–104  
 early infection, 106–107, 106*f*  
 genome, 104–106  
 functions of, 105*t*  
 replication  
 eukaryotic replication, 107–111, 110*t*  
 viral replication, 111–123
- PARK2*, 5
- Pathogen-associated molecular patterns (PAMPs), 296, 297
- Patient Protection and Affordable Care Act of 2010, 15
- Periodontitis, and head and neck squamous cell carcinoma, 39
- PI3 K-mTOR signaling circuitry  
 in HPV-associated oral malignancies, targeting, 153–163  
 activation of, 157–160, 158*t*, 159*f*  
 in head and neck cancer, 160–161  
 in HPV(+) oral cancers, 161–162  
 p53/Rb tumor suppression network, E6 and E7 viral proteins disrupting, 156–157
- PIK3CA mutations  
 in HPV-positive CSCC, 185  
 in HPV-positive HNSCC, 179–180, 185  
 in nasopharyngeal carcinoma, 186–187
- PIMI*, 4
- Pirisi, Lucia, 43
- Platinum/5-FU (PF), for OPSCC/CSCC, 221
- Polymerase chain reaction (PCR), 46
- Posterior pharyngeal wall cancer, 200
- PRIMA-1, 273–274
- Primary tumor presentation, of oropharyngeal cancer, 199
- Programmed death ligand 1 (PD-L1), 294  
 immunosuppressive role of, 300–301, 300*f*
- Programmed death-1 (PD-1), 259, 275  
 immunosuppressive role of, 300–301, 300*f*
- Psyrrri, Amanda, 213
- Q**
- Quality of life (QOL), TORS and, 238–239
- R**
- Racial disparities, 48–64  
 access to care, 58  
 biologic determinants, 63–64  
 detection and treatment disparities, 60–61

- health insurance disparities, 58–60
  - in HPV prevalence/activity, 54–58
    - HPV-inactive OPSCC, 56–57
    - lower prevalence, 55–56
    - no differences, 57–58
  - incidence and mortality rates for
    - age-adjusted, 48, 49*t*
    - decreasing over time, 52–53, 53*f*, 54*f*
    - national and regional data, 49–51
  - lifestyle determinants, 62
  - oral HPV prevalence, determinants of, 62–63
  - social determinants, 58
  - tobacco and alcohol consumption, 61–62
  - Radiation sensitivity, 243–276
    - altered, clinical evidence of, 253–255
    - future directions of, 273–276
    - increased, mechanisms of, 255–262, 262*f*
      - intrinsic differences and cellular radiosensitivity, 255–258, 257*f*
      - tumor microenvironment, 258–262
    - treatment de-intensification
      - clinical trials, 266–272, 267–268*t*
      - dose reduction, risks and benefits of, 262–264, 263*t*
      - patient identification, 265–266, 266*t*
  - Radiotherapy, for OPSCC, 220
  - Reactive oxygen species (ROS)
    - in E2 cell metabolism, 82*t*
    - mitochondrial, 76
    - scavenger, 6
  - Recurrent cancer, 236
  - Regulatory T cells (Tregs), 299
  - Rieckmann, Thorsten, 243
- S**
- Schmitt, Nicole C., 291
  - Sex
    - and head and neck squamous cell carcinoma, 33–37, 34–36*t*
    - and squamous cell carcinoma of the oropharynx, 25, 31*f*
  - Sharon Stack, M., 133
  - Silvio Gutkind, J., 153
  - Smith, Eric A., 69
  - Smoking. *See* Tobacco consumption
    - and cervical squamous cell carcinoma, 218–219
    - and head and neck squamous cell carcinoma, 6, 32–33
    - and squamous cell carcinoma of oropharynx, 218–219
  - Social determinants, of OPSCC disparities, 58
  - Soft palate cancers, 200
  - Spectral karyotyping (SKY), 4
  - Spindle assembly checkpoint (SAC), 87
  - Squamous cell carcinoma of oropharynx (OPSCC)
    - and CSCC, similarities between, 214–224
    - epidemiology, 217
    - etiology of, 217–218
    - HPV on outcome, impact of, 221–222
    - HPV-type distribution, 218
    - molecular pathogenesis, 223–224
    - primary and secondary prevention, 222–223
    - prognosis, 219–220
    - risk factors, 218–219
    - treatment, 220–221
  - HPV-associated
    - additional work-up of, 204–205
    - behavioral correlates of, 24–32
    - clinical evaluation of, 201, 202*f*
    - clinical presentation of, 195–200
    - epidemiology of, 1–18
    - imaging assessment of, 202–204, 203*f*, 204*f*
    - incidence of, 12–13
    - microRNA profiles of, 133–147
    - prevalence of, 10–11
    - risk factors of, 12
    - staging of, 205, 207–208*t*
  - HPV-positive, features of, 13–14
  - racial disparities in
    - access to care, 58
    - biologic determinants, 63–64
    - detection and treatment disparities, 60–61
    - HPV prevalence/activity, 54–58
    - health insurance disparities, 58–60
    - HPV-inactive OPSCC, in black patients, 56–57
    - incidence and mortality rates for, 48–54, 54*f*
    - lifestyle determinants, 62
    - oral HPV prevalence, determinants of, 62–63
    - social determinants, 58
    - tobacco and alcohol consumption, 61–62
  - Staging
    - of HPV (+) oropharyngeal cancer, 209
    - of oropharyngeal cancer, 205, 207–208*t*
  - Surgical perspective, in oropharyngeal cancer management, 231–240

- surgical robotic technology under
    - development, 239–240
    - technique, 232–236, 232*f*, 233*f*
  - transoral robotic surgery. *See* Transoral robotic surgery (TORS)
- T**
- TAP-1, 297
  - TAP-2, 297
  - Tobacco consumption. *See* Smoking
    - disparities in, 61–62
    - and head and neck squamous cell carcinoma, 37–38, 44
  - Toll-like receptors (TLR), 296–297
  - Tomar, Swati, 43
  - Tongue base cancer, 200
  - Tonsil cancer, 199–200, 199*f*
  - Tonsils, 1, 6, 8, 10
    - miR-9 expression and, 139–141
  - TP53 mutations, in HPV-positive HNSCC, 177–179
  - Transmission of oral/cervical HPV infection, 215–216
  - Transoral laser microsurgery (TLM), 234
  - Transoral robotic surgery (TORS), 231–235, 232*f*, 271–272
    - complications of, 239
    - limitations of, 234
    - and oncologic outcomes
      - adjuvant therapy, rates of, 237
      - locoregional control, 237
      - positive margins, 236–237
      - survival, 237–238
      - treatment de-intensification, 238
    - and quality of life, 238–239
  - Treatment de-intensification
    - clinical trials, 266–272, 267–268*t*
      - dose reduction, 270
      - EGFR inhibition, 269–270
      - induction chemotherapy, 270–271
      - surgery, 271–272
    - dose reduction, risks and benefits of, 262–264, 263*t*
    - patient identification, 265–266, 266*t*
  - Tuberous sclerosis complex protein 2 (TSC2), 156
  - Tumor immunology, 261
  - Tumor microenvironment, radiation
    - sensitivity on
      - hypoxia, 258–259
      - immune responses, 259–262
  - Tumor necrosis factor alpha (TNF- $\alpha$ ), 296
  - Tumor-infiltrating lymphocytes (TILs), 299
    - CD8+, 259–260
    - PD-1, 259
- U**
- Ubch10, 88
  - Ubiquitin ligase, 2, 70, 78*t*, 88, 256
  - UPCI cell lines
    - SCC070, 4
    - SCC090, 3, 4
    - SCC152, 3, 4
    - SCC154, 3
  - Upstream regulatory region (URR), 44, 104, 114
    - of BPV1, 115*f*
    - E2BS in, 116, 117
    - HPV18, 105
- V**
- Vaccination, 14–17
    - MenACWY, 15
    - Tdap, 15
  - Vaccines, preventive, for HPV infection, 302–303
  - Vaccines for Children Program, 14–15
  - Vascular endothelial growth factor (VEGF), 74
  - Viral life cycle, 111
  - Viral replication, 111–123
    - DNA damage response, 122–123
    - E1 protein, 116–117
    - E1:E2 interaction, 118
    - E2 protein, 117–118
    - E5 protein, 120
    - E6 protein, 119–120
    - E7 protein, 119–120
    - homologous recombination, 122–123
    - host factors in
      - Brd4, role of, 121–122
      - general factors, 121
    - maintenance requirements for
      - DNA-protein complex, 116
      - DNA sequence requirements, 114–115, 115*t*
      - E1 and E2 proteins, 115–116
    - modes of
      - cell types and cell cycle dependence, 113
      - differentiation and integration, 113–114
      - phosphorylation, 118–119
    - stages of
      - amplification, 112
      - initial replication, 111
      - maintenance, 111–112
      - tethering factors, 122
  - Virus-host interactions, 121–123

**W**

Wells, Susanne I., 69

Whole body positron emission tomography/  
CT (whole body PET/CT), 204

Whole exome sequencing (WES), 173, 175*t*,  
183, 185

Whole genome sequencing (WGS), 4, 5, 85,  
185

**X**

*Xenopus laevis*, eukaryotic DNA replication,  
107

**Y**

Yin Yang 1 (YY1), 104

Younger patients, 243

HPV positive (HPV +) tumors in, 69

HPV + OPSCC in, 136, 210, 244

OPSCC in, 11

Young women, 216

**Z**

ZEB1, 73, 78*t*, 79*t*

ZEB2, 73, 78*t*, 79*t*

Zinc finger protein

ZFP99, 174*f*

ZFP750, 174, 175

ZFP804B, 174*f*

ZFPX4, 175*f*